Your browser doesn't support javascript.
Lung perfusion assessed by SPECT/CT after a minimum of three months anticoagulation therapy in patients with SARS-CoV-2-associated acute pulmonary embolism: a retrospective observational study.
Berghaus, Thomas M; Bader, Stefanie; Faul, Christian; Haberl, Sabine; Schwarz, Florian; Liebich, Alessandro; Dierks, Alexander; Kircher, Malte; Lapa, Constantin; Pfob, Christian H.
  • Berghaus TM; Department of Cardiology, Respiratory Medicine and Intensive Care, University Hospital Augsburg, University of Augsburg, Stenglinstrasse 2, D-86156, Augsburg, Germany. thomas.berghaus@uk-augsburg.de.
  • Bader S; Ludwig-Maximilians-University Munich, Munich, Germany. thomas.berghaus@uk-augsburg.de.
  • Faul C; Department of Cardiology, Respiratory Medicine and Intensive Care, University Hospital Augsburg, University of Augsburg, Stenglinstrasse 2, D-86156, Augsburg, Germany.
  • Haberl S; Department of Cardiology, Respiratory Medicine and Intensive Care, University Hospital Augsburg, University of Augsburg, Stenglinstrasse 2, D-86156, Augsburg, Germany.
  • Schwarz F; Department of Cardiology, Respiratory Medicine and Intensive Care, University Hospital Augsburg, University of Augsburg, Stenglinstrasse 2, D-86156, Augsburg, Germany.
  • Liebich A; Department of Radiology, University Hospital Augsburg, University of Augsburg, Augsburg, Germany.
  • Dierks A; Ludwig-Maximilians-University Munich, Munich, Germany.
  • Kircher M; Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Lapa C; Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Pfob CH; Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Respir Res ; 23(1): 296, 2022 Oct 31.
Article in English | MEDLINE | ID: covidwho-2098345
ABSTRACT

BACKGROUND:

Anticoagulant treatment is recommended for at least three months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related acute pulmonary embolism (PE), but the persistent pulmonary clot burden after that time is unknown.

METHODS:

Lung perfusion was assessed by ventilation-perfusion (V/Q) SPECT/CT in 20 consecutive patients with SARS-CoV-2-associated acute PE after a minimum of three months anticoagulation therapy in a retrospective observational study.

RESULTS:

Remaining perfusion defects after a median treatment period of six months were observed in only two patients. All patients (13 men, seven women, mean age 55.6 ± 14.5 years) were on non-vitamin K direct oral anticoagulants (DOACs). No recurrent venous thromboembolism or anticoagulant-related bleeding complications were observed. Among patients with partial clinical recovery, high-risk PE and persistent pulmonary infiltrates were significantly more frequent (p < 0.001, respectively).

INTERPRETATION:

Temporary DOAC treatment seems to be safe and efficacious for resolving pulmonary clot burden in SARS-CoV-2-associated acute PE. Partial clinical recovery is more likely caused by prolonged SARS-CoV-2-related parenchymal lung damage rather than by persistent pulmonary perfusion defects.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Embolism / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Respir Res Year: 2022 Document Type: Article Affiliation country: S12931-022-02188-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Embolism / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Respir Res Year: 2022 Document Type: Article Affiliation country: S12931-022-02188-2